Q² Solutions Expands Genomics Capabilities in Europe
By Default Author
Morrisville, NC – March 27, 2019 - Q2 Solutions, a leading clinical trial laboratory services organization, proudly announces the expansion of genomics capabilities in Edinburgh, Scotland, including Next Generation Sequencing, exome sequencing, RNA sequencing, and Whole Human Genome sequencing. Recently adding genomics services in Beijing, China in 2018, this expansion into Europe communicates a continued investment into supporting the global drug development needs of customers around the world.
In addition to Q2 Solutions’ USA laboratory’s CAP, CLIA and New York State certifications and China and UK’s CAP and CAP ISO 15189 certifications, each laboratory location is compliant with current Europe GDP requirements, allowing for a seamless sample transfer across sites.
Q2 Solutions’ USA, China, and UK facilities operate utilizing the same processes, methodologies, and SOP’s across locations, with NovaSeq 6000 among the instrumentation at each site. This implementation of harmonized global infrastructure demonstrates the commitment to invest in today while scaling for the future of global clinical trials. To assure alignment across sites, all method deployments are driven by Q2 Solutions subject matter experts. Local staff members are managed directly by leaders within the Q2 Solutions | EA Genomics Center of Excellence and leverage development scientists and other internal resources to drive process excellence. Each global trial is assigned a global project manager for client alignment.
“With the ever-expanding use of genomic technologies in clinical trials, we are proud to now offer genomic laboratory services at three global locations. Notably, this expansion into Europe allows Q2 Solutions to support global studies involving next-generation sequencing-based companion diagnostics from multiple global laboratories.”, says Kellie Yarnell, VP, Genomic Laboratories.
About Q2 Solutions
Q2 Solutions is a leading clinical trial laboratory services organization with end-to-end laboratory services and secure, enterprise-wide biospecimen and consent management solutions. With a relentless focus on quality and innovation, Q2 Solutions uses its global experience and scientific expertise to transform science and data into actionable medical insights that help customers improve human health. Q2 Solutions’ industry-leading genomic and bioinformatics services provide customers with DNA and RNA sequencing and other testing as well as the ability to mine data for invaluable insights for drug discovery, precision medicine and clinical development. Q2 Solutions | EA Genomics works with clients, using a wide array of technology platforms, to ensure maximum efficiency and quality delivery for every study. A joint venture of IQVIA (formerly QuintilesIMS) and Quest Diagnostics, Q2 Solutions combines the best of each parent organization’s clinical trials laboratory services capabilities to fulfill its mission of treating each sample as if a life depends on it. To learn more, visit www.q2labsolutions.com.
By Default Author
